Skip to main content
. 2021 Mar 13;24(4):970–977. doi: 10.1007/s10120-021-01156-x

Fig. 1.

Fig. 1

Efficacy outcomes in the GEJC and GC subgroups. a OS in the GEJC subgroup. b OS in the GC subgroup. c PFS in the GEJC subgroup. d PFS in the GC subgroup. CI: confidence interval, ECOG PS: Eastern Cooperative Oncology Group performance status, GEJC: gastroesophageal junction cancer, GC: gastric cancer, HR: hazard ratio, PFS: progression-free survival, OS: overall survival